163 related articles for article (PubMed ID: 6220312)
1. [Paroxysmal nocturnal hemoglobinuria. Increase in proteins of the alternative complement pathway].
de Gramont A; Kazatchkine M; Maillet F; Blanche M; Debray J
Presse Med; 1983 Mar; 12(12):747-50. PubMed ID: 6220312
[TBL] [Abstract][Full Text] [Related]
2. Comparison of binding characteristics of factors B and H to C3b on normal and paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Baker PJ; Rosse WF
J Immunol; 1983 Nov; 131(5):2484-9. PubMed ID: 6226743
[TBL] [Abstract][Full Text] [Related]
3. Paroxysmal nocturnal hemoglobinuria: deficiency in factor H-like functions of the abnormal erythrocytes.
Pangburn MK; Schreiber RD; Trombold JS; Müller-Eberhard HJ
J Exp Med; 1983 Jun; 157(6):1971-80. PubMed ID: 6222136
[TBL] [Abstract][Full Text] [Related]
4. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
Yuan X; Gavriilaki E; Thanassi JA; Yang G; Baines AC; Podos SD; Huang Y; Huang M; Brodsky RA
Haematologica; 2017 Mar; 102(3):466-475. PubMed ID: 27810992
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Schmidt CQ; Harder MJ; Nichols EM; Hebecker M; Anliker M; Höchsmann B; Simmet T; Csincsi ÁI; Uzonyi B; Pappworth IY; Ricklin D; Lambris JD; Schrezenmeier H; Józsi M; Marchbank KJ
Immunobiology; 2016 Apr; 221(4):503-11. PubMed ID: 26792457
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the complement sensitivity of paroxysmal nocturnal hemoglobinuria erythrocytes.
Parker CJ; Wiedmer T; Sims PJ; Rosse WF
J Clin Invest; 1985 Jun; 75(6):2074-84. PubMed ID: 4008653
[TBL] [Abstract][Full Text] [Related]
7. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
8. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
[TBL] [Abstract][Full Text] [Related]
9. Increased enzymatic activity of the alternative pathway convertase when bound to the erythrocytes of paroxysmal nocturnal hemoglobinuria.
Parker CJ; Baker PJ; Rosse WF
J Clin Invest; 1982 Feb; 69(2):337-46. PubMed ID: 6915939
[TBL] [Abstract][Full Text] [Related]
10. A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement.
Lindorfer MA; Pawluczkowycz AW; Peek EM; Hickman K; Taylor RP; Parker CJ
Blood; 2010 Mar; 115(11):2283-91. PubMed ID: 20068220
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of factors of the alternative pathway].
Takemura S; Kondo M
Nihon Rinsho; 1990 Feb; 48 Suppl():630-3. PubMed ID: 2141369
[No Abstract] [Full Text] [Related]
12. Development and application of an enzyme-linked immunosorbent assay for the quantitation of alternative complement pathway activation in human serum.
Mayes JT; Schreiber RD; Cooper NR
J Clin Invest; 1984 Jan; 73(1):160-70. PubMed ID: 6418767
[TBL] [Abstract][Full Text] [Related]
13. Molecular basis of the enhanced susceptibility of the erythrocytes of paroxysmal nocturnal hemoglobinuria to hemolysis in acidified serum.
Wilcox LA; Ezzell JL; Bernshaw NJ; Parker CJ
Blood; 1991 Aug; 78(3):820-9. PubMed ID: 1713516
[TBL] [Abstract][Full Text] [Related]
14. Complement 1 inhibitor is a regulator of the alternative complement pathway.
Jiang H; Wagner E; Zhang H; Frank MM
J Exp Med; 2001 Dec; 194(11):1609-16. PubMed ID: 11733575
[TBL] [Abstract][Full Text] [Related]
15. Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo.
Devine DV; Siegel RS; Rosse WF
J Clin Invest; 1987 Jan; 79(1):131-7. PubMed ID: 2432087
[TBL] [Abstract][Full Text] [Related]
16. Lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by acid-activated serum.
Hänsch G; Hammer C; Jiji R; Rother U; Shin M
Immunobiology; 1983 Mar; 164(2):118-26. PubMed ID: 6852860
[TBL] [Abstract][Full Text] [Related]
17. Affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria are deficient in the complement regulatory protein, decay accelerating factor.
Nicholson-Weller A; March JP; Rosenfeld SI; Austen KF
Proc Natl Acad Sci U S A; 1983 Aug; 80(16):5066-70. PubMed ID: 6576376
[TBL] [Abstract][Full Text] [Related]
18. The alternative pathway of complement.
Pangburn MK; Müller-Eberhard HJ
Springer Semin Immunopathol; 1984; 7(2-3):163-92. PubMed ID: 6238433
[No Abstract] [Full Text] [Related]
19. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
Rosenfeld SI; Jenkins DE; Leddy JP
J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of alternative pathway and factor B haemolytic activities in patients with systemic lupus erythematosus: correlations with the alternative pathway regulatory proteins.
Aguado MT; Perrin LH; Ramirez R; Miescher PA; Lambert PH
Clin Exp Immunol; 1980 Dec; 42(3):495-505. PubMed ID: 6163579
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]